The U.S. Food and Drug Administration today approved Remicade (infliximab) to treat moderately to severely active ulcerative colitis (UC) in children older than 6 years who have had inadequate response to conventional therapy.

The U.S. Food and Drug Administration today approved Inflectra (infliximab-dyyb) for multiple indications. Inflectra is administered by intravenous infusion. This is the second biosimilar approved by the FDA.

The US Food and Drug Administration (FDA) has approved the infliximab biosimilar product infliximab-abda (Renflexis, Samsung Bioepis) for multiple indications.

Read about how Remicade can reduce the chance of someone with ulcerative colitis needing their colon removed.

For relief from Crohn's disease, a combination of biologic and immunosuppressive therapies appears to be the best initial treatment, according to findings from a clinical trial.

The US Food and Drug Administration's (FDA's) Arthritis Drugs Advisory Committee gave its backing to CT-P13, a drug that would be the first biosimilar monoclonal antibody approved in the United States.

Read about the new study showing how new Rheumatoid Arthritis drugs such as Remicade and Enbrel raise the risk of skin cancer on RxList

RA patients treated with TNF blockers have higher rates of skin cancer than patients who take other disease-modifying antirheumatic drugs, or DMARDs, new studies show.

Read the report of increased adverse drug effects reported to the FDA such as acetaminophen, Tylenol, insulin, Celebrex and more on RxList

Biosimilar tumor necrosis factor-alpha inhibitors appear equivalent to the branded original versions, according to a systematic review and meta-analysis.

Patients with inflammatory bowel disease or IBD may be at an increased risk for getting skin cancer, according to a study presented at the American College of Gastroenterology's annual meeting in San Diego.